HRA Proposes OTC Norgestrel Birth Control
HRA has worked with Ibis Reproductive Health, which supports the Free the Pill advocacy group, to conduct research for a norgestrel switch NDA.
You may also be interested in...
'Catch-Up’ Symptoms Slow Perrigo In Cold Season
Strong cough/cold season forecast bodes well for upper respiratory and other OTCs Perrigo provides as private label and store brand products, but it isn’t expecting to capitalize in the Americas due to lingering impacts from supply chain and production disruptions linked to the COVID-19 pandemic.
People On The Move: HRA Pharma, Hofseth BioCare, UK CHM
A round-up of the latest people moves in Europe's health and wellness markets: HRA Pharma's CEO David Wright steps down; Hofseth BioCare promotes Ødegård to lead the company; and the UK's Commission on Human Medicines appoints nine new members.
US Q2 Consumer Health Earnings Preview: Horizon Brightens Beyond Current Questions, Challenges?
Consumer health product firms’ vistas include challenges of supply chain disruptions lingering from pandemic’s impact as well as potential for marketplace restrictions as additional varieties of the novel coronavirus spread. Clouds also include shifts in consumer spending, increases in costs caused by inflation and foreign exchange headwinds as the value of the US dollar strengthens against other currencies.